Inosine

Inosine

SCHEMBL222073

O=c1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)[nH]1.OC[C@H]1O[C@@H](n2cnc3c(O)ncnc32)[C@H](O)[C@@H]1O

nearest known ligand 0.67

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC29A1 Q99808 8/20 0.67
SLC28A1 O00337 2/20 0.67
SLC28A2 O43868 2/20 0.67
SLC28A3 Q9HAS3 2/20 0.67
STAT6 P42226 2/20 0.57
MAPK1 P28482 2/20 0.57
SMN1; SMN2 Q16637 2/20 0.57
DPP4 P27487 1/20 0.57
MEN1 O00255 1/20 0.57
MAP3K7 O43318 1/20 0.57
GAPDH P04406 1/20 0.57
ADORA3 P0DMS8 1/20 0.57
ADORA2A P29274 1/20 0.57
ADORA2B P29275 1/20 0.57
ADORA1 P30542 1/20 0.57
PI4KA P42356 1/20 0.57
KMT2A Q03164 1/20 0.57
PI4K2B Q8TCG2 1/20 0.57
DOT1L Q8TEK3 1/20 0.57
PI4K2A Q9BTU6 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Adenosine SCHEMBL9591334 0.95 ADORA3 (0.67) SLC29A1SLC28A1SLC28A2SLC28A3STAT6
Guanosine SCHEMBL27427138 0.91 P2RY2 (0.57) SLC29A1SLC28A1SLC28A2SLC28A3STAT6
Inosine SCHEMBL23300589 0.90 RNASEL (0.64) SLC29A1SLC28A1SLC28A2SLC28A3ADORA1
Adenosine SCHEMBL8351411 0.90 ADORA3 (0.74) SLC29A1SLC28A1SLC28A2SLC28A3STAT6
Adenosine SCHEMBL2248919 0.90 ADORA3 (0.74) SLC29A1SLC28A1SLC28A2SLC28A3STAT6
Inosine SCHEMBL29860062 0.87 SLC29A1 (0.73) SLC29A1SLC28A1SLC28A2SLC28A3STAT6
Inosine SCHEMBL5066239 0.86 SLC29A1 (0.56) SLC29A1SLC28A1SLC28A2SLC28A3STAT6
Inosine SCHEMBL330178 0.85 SLC29A1 (0.75) SLC29A1SLC28A1SLC28A2SLC28A3STAT6
Inosine SCHEMBL4110068 0.85 SLC29A1 (0.75) SLC29A1SLC28A1SLC28A2SLC28A3STAT6
Inosine SCHEMBL2046912 0.85 SLC29A1 (0.75) SLC29A1SLC28A1SLC28A2SLC28A3STAT6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 198 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2019148062-A1 FISH ATTRACTANTS MITCHELL GREGORY (US) 2019-08-01 WO claimed
EP-2601209-A1 GENOMICS OF ACTINOPLANES UTAHENSIS Bayer Intellectual Property GmbH (DE) 2013-06-12 EP claimed
WO-2012016960-A1 GENOMICS OF ACTINOPLANES UTAHENSIS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2012-02-09 WO claimed
JP-61207394-A None JP disclosed
US-20240199709-A1 FUSION PROTEINS, RECOMBINANT BACTERIA, AND METHODS FOR USING RECOMBINANT BACTERIA SPOGEN BIOTECH INC (US) 2024-06-20 US disclosed
US-11905315-B2 Fusion proteins, recombinant bacteria, and methods for using recombinant bacteria SPOGEN BIOTECH INC. (US) 2024-02-20 US disclosed
EP-3578659-B1 ARTIFICIAL NUCLEIC ACID MOLECULES FOR IMPROVED PROTEIN OR PEPTIDE EXPRESSION CureVac SE (DE) 2023-11-01 EP disclosed
CN-114028431-A Compositions comprising bacterial strains 4D制药研究有限公司 2022-02-11 CN disclosed
EP-3527662-B1 NUCLEIC ACID COMPRISING OR CODING FOR A HISTONE STEM-LOOP AND A POLY(A) SEQUENCE OR A POLYADENYLATION SIGNAL FOR INCREASING THE EXPRESSION OF AN ENCODED TUMOUR ANTIGEN CUREVAC AG (DE) 2022-01-26 EP disclosed
US-20210393755-A1 NUCLEIC ACID COMPRISING OR CODING FOR A HISTONE STEM-LOOP AND A POLY(A) SEQUENCE OR A POLYADENYLATION SIGNAL FOR INCREASING THE EXPRESSION OF AN ENCODED TUMOUR ANTIGEN CUREVAC AG (DE) 2021-12-23 US disclosed
CN-113423413-A Compositions comprising bacterial strains 4D制药研究有限公司 2021-09-21 CN disclosed
WO-2002100530-A2 METHOD FOR CONTROLLING FERMENTATION DEGUSSA AG (DE) 2002-12-19 WO disclosed
WO-2002074798-A2 THE GENOME OF A BIFIDOBACTERIUM SOCIETE DES PRODUITS NESTLE S.A. (CH) 2002-09-26 WO disclosed
CN-1371417-A Corynebacterium glutamicum genes encoding metabolic pathway proteins BASF AG (DE) 2002-09-25 CN disclosed
US-20020132263-A1 Enzyme detection/assay method and substrates NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2002-09-19 US disclosed
EP-1227152-A1 Bacterial strain and genome of bifidobacterium Société des Produits Nestlé S.A. (CH) 2002-07-31 EP disclosed
US-6379911-B2 ANALYZING NUCLEOSIDE HYDROLASES; DETECTING PARASITES ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY 2002-04-30 US disclosed
US-20010019823-A1 ENZYME DETECTION/ASSAY METHOD AND SUBSTRATES NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2001-09-06 US disclosed
WO-1997031008-A1 ENZYME DETECTION/ASSAY METHOD AND SUBSTRATES INDUSTRIAL RESEARCH LIMITED (NZ) 1997-08-28 WO disclosed
JP-S61207394-A MONOMER HAVING NUCLEOTIDE-LIKE STRUCTURE AND PRODUCTION THEREOF MITSUBISHI CHEM IND LTD 1986-09-13 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010019823-A1 ENZYME DETECTION/ASSAY METHOD AND SUBSTRATES PNP, TREH, XDH SLC29A1 234/4885SLC28A1 558/4885SLC28A2 604/4885
US-20210393755-A1 NUCLEIC ACID COMPRISING OR CODING FOR A HISTONE STEM-LOOP AND A POLY(A) SEQUENCE OR A POLYADENYLATION SIGNAL FOR INCREASING THE EXPRESSION OF AN ENCODED TUMOUR ANTIGEN HNRNPH3, HNRNPL, CPSF6 SLC29A1 2698/4885SLC28A1 2605/4885SLC28A2 3032/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.